Norgine B.V. enters into an agreement to dispose of its rights to EMSELEX® (darifenacin) in Europe to pharma&

01 October 2020



AMSTERDAM, The Netherlands. 1 October 2020, 11:00 BST / 12:00 CET. Norgine B.V. (“Norgine”), today announced that its wholly-owned subsidiary, SpePharm A.G., has entered into an agreement to dispose of its rights to EMSELEX® (darifenacin) in Europe to pharma& (“pharma&”).

EMSELEX® is indicated for the treatment of overactive bladder syndrome in adult patients. It is used to treat urge incontinence i.e. the sudden lack of control over urination and the increased urinary frequency and urgency that are associated with the syndrome, helping patients to prevent unwanted urination. [1] 

Peter Stein, Chief Executive Officer of Norgine said, “Our commitment to helping patients drives everything we do.  We are delighted to announce this transaction with pharma& which will enable Norgine to focus on its larger growth opportunities while ensuring that patients across Europe continue to benefit from this important therapy.  We wish pharma& the very best.”

Elmar Zagler and Frank Rotmann, Founders of pharma& commented, “With acquiring EMSELEX® we further strengthen our presence in Specialty Care and Urology alike. We look forward to continue to satisfy patient needs for this well-established therapy option in Europe and thank Norgine for their trust and support.”   

Norgine incorporated EMSELEX® into its portfolio following the acquisition of Merus Labs International Inc in July 2017, which strengthened Norgine’s position as a leading European specialist pharmaceutical company.




For further information please contact:

Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883
Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477
Follow us @norgine


Notes to Editors:

About EMSELEX® (darifenacin)

EMSELEX® (darifenacin) is a prescription only medicine indicated for overactive-bladder syndrome in adults. It is used to treat the urge incontinence, increased urinary frequency and urgency that are associated with the syndrome. Darifenacin is an anticholinergic medicine. It blocks the muscarinic M3 receptor. In the bladder, this causes the muscles that push urine out of the bladder to relax. This leads to an increase in the capacity of the bladder and changes in the way the bladder contracts, resulting in fewer bladder contractions. This enables EMSELEX® to help prevent unwanted urination. [1] 


About Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2019 and generated more than €419 million in net product sales, a growth of 6% over 2018.

Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

In 2012, Norgine established Norgine Ventures, a complementary business which supports innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit


About pharma&

pharma& is a privately owned company aiming at satisfying needs for unique, original,Specialty Care niche products in Europe. Our commitment to patient needs for well established original Specialty Care medicines and our Pan-European presence of own subsidaries, affliliated companies and partnerships secure sustainable product availibilty across all European markets. Headquartered in Vienna, in the Heart of Europe we deliver our products and reach patients across the entire European landscape. We are proud of our niche product focus and “every patient counts” commitment as well as of our strong partnership network. For more information, please visit



[1] EMSELEX® Summary of Product Characteristics (SmPC). Available at:  Accessed October 2020